Recombinant viral vectors: Cancer vaccines

A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma Multiforme

2000 • 701 citations

Vaccinia virus: a selectable eukaryotic cloning and expression vector.

1982 • 663 citations

The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.

1996 • 552 citations

Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity

2004 • 374 citations

Persistence and Expression of the Herpes Simplex Virus Genome in the Absence of Immediate-Early Proteins

1998 • 373 citations

Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses

2000 • 363 citations

Applications of pox virus vectors to vaccination: an update.

1996 • 348 citations

Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma Antigens

1998 • 306 citations

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

2000 • 300 citations

Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

2004 • 298 citations

MUC1: the polymorphic appearance of a human mucin

2000 • 271 citations

Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group

2004 • 252 citations

The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors

1998 • 235 citations

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

2002 • 230 citations

Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4

2003 • 209 citations

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

1997 • 209 citations

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

1999 • 206 citations

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

2000 • 205 citations

An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology.

1990 • 203 citations

Phase I Study in Cancer Patients of a Replication-Defective Avipox Recombinant Vaccine That Expresses Human Carcinoembryonic Antigen

1999 • 201 citations

Prospects for Control of Herpes Simplex Virus Disease through Immunization

2000 • 200 citations

Development and optimization of an adenovirus production process

2004 • 180 citations

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

2001 • 173 citations

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

2003 • 172 citations

Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial

2006 • 166 citations

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

2004 • 163 citations

Neutralizing Antibodies and CD8 ⁺ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors

2004 • 161 citations

A Genetically Inactivated Herpes Simplex Virus Type 2 (HSV-2) Vaccine Provides Effective Protection against Primary and Recurrent HSV-2 Disease

1997 • 161 citations

Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity

2005 • 157 citations

Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.

2000 • 154 citations

Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene — a phase I/II clinical protocol

2003 • 147 citations

A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)

1995 • 144 citations

Recombinant Vaccinia Virus Encoding Human MUC1 and IL2 as Immunotherapy in Patients With Breast Cancer

2000 • 126 citations

Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.

2001 • 126 citations

Deletion of the Virion Host Shutoff Protein (vhs) from Herpes Simplex Virus (HSV) Relieves the Viral Block to Dendritic Cell Activation: Potential of vhs⁻HSV Vectors for Dendritic Cell-Mediated Immunotherapy

2003 • 121 citations

T‐cell recognition of melanoma‐associated antigens

2000 • 114 citations

Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group

2001 • 107 citations

Pathogenesis and potential antiviral therapy of complications of smallpox vaccination

2003 • 103 citations

T-cell recognition of melanoma-associated antigens

2000 • 102 citations

Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.

2003 • 99 citations

Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.

2002 • 96 citations

Comparative Analysis of the In Vivo Expression of Tyrosinase, MART-1/Melan-A, and gp100 in Metastatic Melanoma Lesions: Implications for Immunotherapy

1998 • 94 citations

Attenuated Modified Vaccinia Virus Ankara Can Be Used as an Immunizing Agent under Conditions of Preexisting Immunity to the Vector

2000 • 92 citations

Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1–Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A

2002 • 92 citations

Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination

2001 • 90 citations

Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.

1999 • 90 citations

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

2003 • 90 citations

Immunotherapy of bladder cancer

1997 • 87 citations

Recombinant viruses as vaccines against viral diseases

2005 • 83 citations

Cancer Vaccines and Immunotherapy

2000 • 82 citations

What Makes MUC1 a Tumor Antigen?

2005 • 73 citations

Safety profile of recombinant canarypox HIV vaccines

2003 • 69 citations

Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.

2003 • 69 citations

Recombinant viruses as tools to induce protective cellular immunity against infectious diseases.

2004 • 68 citations

Alphavirus vectors for vaccine production and gene therapy

2003 • 66 citations

Melanoma-associated antigens recognized by cytotoxic T lymphocytes

1998 • 66 citations

Development and characterization of a cell line for large‐scale, serum‐free production of recombinant adeno‐associated viral vectors

2004 • 65 citations

Herpes Simplex Virus Vectors Elicit Durable Immune Responses in the Presence of Preexisting Host Immunity

2002 • 64 citations

Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials

2005 • 62 citations

Improved Packaging System for Generation of High-Level Noncytotoxic HSV-1 Amplicon Vectors Using Cre-loxP Site-Specific Recombination to Delete the Packaging Signals of Defective Helper Genomes

2003 • 62 citations

Breast Cancer Immunotherapy

2017 • 59 citations

Development of the PANVAC™-VF vaccine for pancreatic cancer

2006 • 59 citations

A Novel Herpes Vector for the High-Efficiency Transduction of Normal and Malignant Human Hematopoietic Cells

1997 • 56 citations

A New Scalable Method for the Purification of Recombinant Adenovirus Vectors

2002 • 55 citations

Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma

2005 • 51 citations

Therapeutic vaccines against melanoma and colorectal cancer

2001 • 51 citations

A Novel Herpes Vector for the High-Efficiency Transduction of Normal and Malignant Human Hematopoietic Cells

1997 • 50 citations

The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1

1999 • 49 citations

Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1–Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A

2002 • 49 citations

Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity

2005 • 48 citations

15th International Congress on Infectious Diseases

2012 • 46 citations

Construction and Characterization of a Triple-Recombinant Vaccinia Virus Encoding B7-1, Interleukin 12, and a Model Tumor Antigen

1998 • 45 citations

Advances in the Development of Non-Human Viral DNA-Vectors for Gene Delivery

2002 • 44 citations

Alphavirus Vectors for Gene Therapy Applications

2001 • 41 citations

Reduced levels of DNA 5-methylcytosine in metastatic variants of the human melanoma cell line MeWo.

1987 • 35 citations

Immune parameters affecting adenoviral vector gene therapy in the brain

1998 • 33 citations

Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus

1991 • 31 citations

Breast Cancer Immunotherapy

2004 • 30 citations

Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy

2006 • 28 citations

Antigens recognized by T-lymphocytes on human tumours

1997 • 27 citations

Monitoring of Human Immunological Responses to Vaccinia Virus

2004 • 27 citations

An Adenovirus Type 5 (Ad5) Amplicon-Based Packaging Cell Line for Production of High-Capacity Helper-Independent ΔE1-E2-E3-E4 Ad5 Vectors

2005 • 27 citations

The immunology of colorectal cancer

2004 • 22 citations

Therapeutic Cancer Vaccines: At Midway Between Immunology and Pharmacology

2005 • 22 citations

Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity

2002 • 21 citations

CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study

2005 • 19 citations

Antigen specific active immunotherapy: lessons from the first decade

2005 • 9 citations

Modest increases in the titers of helper virus-free herpes simplex virus 1 (HSV-1) vectors by packaging in a cell line with inducible expression of HSV-1 VP16 or by treatment with N,N'-hexamethylene-bis-acetamide.

2000 • 6 citations

Packaging Cell Lines for Generating Replication-Defective and Gutted Adenoviral Vectors

2003 • 5 citations

OncoVEX: A family of oncolytic herpes simplex viruses optimised for therapeutic use

2004 • 2 citations

Cited By (0)

Loading...